University of Illinois, College of Medicine, One Illini Drive, Peoria, IL, 61605, USA; Injury Control Research Center, West Virginia University, 886 Chestnut Ridge Road, Morgantown, WV 26506, USA; Center of Excellence for Suicide Prevention, Department of Veterans Affairs, 400 Fort Hill Ave, Canandaigua, NY 14424, USA.
National Drug & Alcohol Research Centre, Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Australia.
Drug Alcohol Depend. 2022 Mar 1;232:109310. doi: 10.1016/j.drugalcdep.2022.109310. Epub 2022 Jan 19.
Identifying solutions to the continued rise in overdose deaths is a public health priority. However, there is evidence of change in recent substance type associated with morbidity and mortality. To better understand the continued rise in overdose deaths, in particular those attributed to opioid and stimulant use disorders, increased knowledge of patterns of use is needed.
Retrospective cohort study of Veterans diagnosed with an opioid or stimulant use disorder between 2005 and 2019. The outcome of interest was diagnosis of substance use disorders, specifically examining combinations of opioid and stimulant use disorders among this population.
A total of 1932,188 Veterans were diagnosed with at least one substance use disorder (SUD) during the study period, 2005 through 2019. While the annual prevalence of opioid use disorder (OUD) diagnoses increased more than 155%, OUD diagnoses absent of any other SUD diagnosis increased by an average of 6.9% (95% CI, 6.4, 7.5) per year between 2005 and 2019. Between 2011 and 2019, diagnoses of co-morbid methamphetamine use disorder (MUD) and OUD increased at a higher rate than other SUD combinations.
The prevalence of comorbid SUD, in particular co-occurring opioid and methamphetamine use disorder, increased at a higher rate than other combinations between 2005 and 2019. These findings underscore the urgent need to offer patients a combination of evidence-based treatments for each co-morbid SUD, such MOUD and contingency management for persons with comorbid opioid and methamphetamine use disorders.
确定持续上升的过量用药死亡人数的解决方案是公共卫生的当务之急。然而,最近与发病率和死亡率相关的物质类型的变化有证据表明。为了更好地了解过量用药死亡人数的持续上升,特别是那些归因于阿片类药物和兴奋剂使用障碍的死亡人数,需要增加对使用模式的了解。
对 2005 年至 2019 年间被诊断为阿片类药物或兴奋剂使用障碍的退伍军人进行回顾性队列研究。感兴趣的结果是物质使用障碍的诊断,特别是在这一人群中检查阿片类药物和兴奋剂使用障碍的组合。
在研究期间,共有 1932188 名退伍军人被诊断出至少有一种物质使用障碍(SUD)。虽然阿片类药物使用障碍(OUD)的年患病率增加了 155%以上,但在 2005 年至 2019 年间,没有任何其他 SUD 诊断的 OUD 诊断每年平均增加 6.9%(95%CI,6.4,7.5)。2011 年至 2019 年间,共患甲基苯丙胺使用障碍(MUD)和 OUD 的诊断率比其他 SUD 组合增长得更快。
共患 SUD 的患病率,特别是同时存在的阿片类药物和甲基苯丙胺使用障碍,在 2005 年至 2019 年间比其他组合以更高的速度增长。这些发现强调了迫切需要为每位共患 SUD 患者提供基于证据的治疗组合,如共患阿片类药物和甲基苯丙胺使用障碍患者的 MOUD 和应急管理。